Use of Tofacitinib in Anti-Synthetase Antibodies Associated with Rapidly Progressive Interstitial Lung Disease. A Case Report

We reported a 64-year-old woman with anti-synthetase antibodies associated with rapidly progressive interstitial lung disease (RP-ILD) presented with respiratory failure. The disease remained active despite two courses of pulse steroid and intravenous cyclophosphamide. She was subsequently treated with tofacitinib with dramatic clinical improvement. Our case demonstrated blockage of JAK1 and JAK3 could be an effective treatment in the initial phase of RP-ILD.